Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rBCG-N-RSV vs BCG in adults ≥60 years
2023-509048-80-01Phase 2Authorised
- Sponsor
- BioTherVax
- Start
- Sep 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of rBCG-N-RSV vaccine in respiratory syncytial virus disease (RSV) and Tuberculosis (TB) (2 arms), sponsored by BioTherVax. Primary endpoints: Local solicited adverse events at injection site, Unsolicited adverse events and 4 more. Planned start Sep 2026; status: authorised.
02
Drugs
rBCG-N-RSV vaccine
03
Conditions
respiratory syncytial virus disease (RSV)Tuberculosis (TB)
Beyond the preview
Go deeper on 2023-509048-80-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509048-80-01.